Dexcom said it has received 56 reports of injuries, including seizures, loss of consciousness, vomiting and other symptoms related to hypoglycemia or hyperglycemia. The FDA listed the issue this week ...
Hosted on MSN
Recall for medical device used by millions of Americans over malfunction that could lead to death
An urgent recall has gone out for a popular medical device used by millions of Americans with diabetes. The US Food and Drug Administration (FDA) has revealed that over two million blood glucose ...
Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, commends the expansion of CGM Medicare coverage to ...
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...
Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
Once paired, you’ll be able to leave your iPhone behind while still getting real-time readings. Once paired, you’ll be able to leave your iPhone behind while still getting real-time readings. is a ...
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE ...
Dexcom, Inc. (NASDAQ: DXCM) issues this press release to supplement its previous customer notification and remind its patients to periodically test the audible alarms and alerts on certain receivers ...
Results from the 2021 MOBILE study, sponsored by Dexcom and using Dexcom CGM, served as the primary piece of clinical evidence that led to this coverage expansion by demonstrating that CGM use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results